GSK Expects To Launch Once-Daily HIV Combo Product Ahead Of Gilead
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline believes its future once-daily combination of Epivir and Ziagen will be stronger than Gilead's pending HIV combination
You may also be interested in...
GSK, Gilead HIV Fixed-Dose Combination Drugs Clear FDA
The approvals of Gilead’s Truvada and GSK’s Epzicom were announced publicly by FDA Acting Commissioner Crawford during a Washington, D.C. luncheon speech. Gilead is shipping Truvada to wholesalers this week. Two month supplies of Epzicom will be available free to patients through participating physicians for a limited time.
GSK, Gilead HIV Fixed-Dose Combination Drugs Clear FDA
The approvals of Gilead’s Truvada and GSK’s Epzicom were announced publicly by FDA Acting Commissioner Crawford during a Washington, D.C. luncheon speech. Gilead is shipping Truvada to wholesalers this week. Two month supplies of Epzicom will be available free to patients through participating physicians for a limited time.
Gilead’s Once-Daily HIV Combo Receives Priority Status; Accelerates Race With GSK
The fixed-dose co-formulation of Viread/Emtriva has an estimated user fee deadline of Sept. 12; a decision on GSK’s combo is expected in August. Results from a study of Viread, Emtriva and Sustiva are due by year end, Gilead said.